

Appendix Table F147. Comparative effectiveness of nonpharmacological treatments on continence (insufficient evidence)

Active	Control	Studies reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)	Evidence
Continence service	Bladder training	1 study ⁵⁸⁸	74	Not significant				Insufficient
Continence service	PFMT	1 study ⁵⁴⁷	33	7.44 (2.00; 27.70)	0.76 (0.53; 0.98)	1 (1; 2)	757 (534; 980)	Insufficient
Continence service	Tele continence service	1 study ⁵⁴²	58	Not significant				Insufficient
PFMT+ reminder	PFMT+ bladder training	1 study ⁴⁷⁹	103	Not significant				Insufficient
PFMT in the supine position	PFMT in both supine and upright positions	1 study ⁴⁹⁷	44	Not significant				Insufficient
Group physiotherapy	Biofeedback	1 study ⁵⁸⁵	40	Not significant				Insufficient
Individual PFMT+BT	Group PFMT	1 study ⁵⁴⁴	530	1.58 (1.05; 2.36)	0.08 (0.00; 0.16)	12 (6; 1003)	81 (1; 161)	Insufficient
Circular muscle exercises (Paula method)	PFMT	1 study ⁵⁵⁹	245	1.50 (1.11; 2.03)	0.17 (0.05; 0.29)	6 (3; 21)	171 (48; 295)	Insufficient
PFMT	PFMT+ Balls	1 study ⁴⁸⁴	37	0.11 (0.01; 1.83)	-0.22 (-0.43; -0.02)	-5 (-52; -2)	-222 (-425; -19)	Insufficient
Physiotherapy in combination with biofeedback	Physiotherapy	1 study ⁵³⁵	40	3.67 (1.20; 11.19)	0.40 (0.13; 0.67)	3 (1; 8)	400 (132; 668)	Insufficient
Weekly posterior tibial nerve simulation	Posterior tibial nerve simulation three times per week	1 study ⁵²⁷	35	Not significant				Insufficient
Vaginal cone	behavioral intervention	1 study ⁶¹⁵	238	Not significant				Insufficient
Conveen Continence device Guard, CCG	Contrelle Continence Tampon, CCT	1 study ⁶⁰⁸	94	Not significant				Insufficient

Appendix Table F147. Comparative effectiveness of nonpharmacological treatments on continence (insufficient evidence) (continued)

Active	Control	Studies reference	Number of subjects	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events 95% CI)	Evidence
Hodge pessary with support	Super tampon	1 study ⁵⁷⁹	40	Not significant				Insufficient
Durasphere	Contigen	1 study ⁴⁸²	52	3.33 (1.03; 10.74)	0.27 (0.05; 0.49)	4 (2; 22)	269 (46; 493)	Insufficient
Urethral device (NEAT)	Reliance insert sterile balloon	1 study ⁵⁹⁰	24	Not significant				Insufficient
Calcium hydroxylapatite (CaHA)	Bovine Dermal Collagen	1 study ⁵⁶⁷	296	Not significant				Insufficient
Peri or transurethral porcine dermal implant injection (Permacol)	Transurethral silicone injection (Macroplastique)	⁴⁸⁷		Not significant				Insufficient
Periurethral route of injection of bulking agent-dextran copolymer	Transurethral route of injection of bulking agent-dextran copolymer	⁵⁹³		Not significant				Insufficient
Macroplastique	Contigen®	1 study ⁵³³	247	1.49 (1.01; 2.18) NS for self reported continence	0.12 (0.01; 0.24)	8 (4; 152)	121 (7; 235)	Insufficient
Autologous myoblasts and fibroblasts	Collagen	1 study ⁵⁹⁸	63	9.50 (2.53; 35.63)	0.81 (0.66; 0.96)	1 (1; 2)	810 (656; 963)	Insufficient
Zuidex Implacer	Contigen Endoscopic guidance	1 study ⁵⁶²	344	Not significant				Insufficient